AI Article Synopsis
- The monoclonal antibody M-DC8 identifies a key group of human blood dendritic cells characterized by the unique carbohydrate modification 6-sulfo LacNAc on PSGL-1.
- Unlike other blood dendritic cells, M-DC8+ dendritic cells do not express the cutaneous lymphocyte antigen (CLA) and do not bind certain selectins, but they do have receptors that help recruit immune cells to inflammation sites.
- These M-DC8+ dendritic cells are notable for their ability to produce significantly higher levels of TNF-alpha when exposed to bacterial components, indicating they may play a crucial role in proinflammatory responses.
Article Abstract
The monoclonal antibody M-DC8 defines a major subset of human blood dendritic cells (DCs). Here we identify the M-DC8 structure as 6-sulfo LacNAc, a novel carbohydrate modification of the P selectin glycoprotein ligand 1 (PSGL-1). In contrast to previously described blood DCs, M-DC8+ DCs lack the cutaneous lymphocyte antigen (CLA) on PSGL-1 and fail to bind P and E selectin. Yet they express anaphylatoxin receptors (C5aR and C3aR) and the Fcgamma receptor III (CD16), which recruit cells to inflammatory sites. While sharing with DC1 the expression of myeloid markers and a potent capacity to prime T cells in vitro, M-DC8+ DCs produce far more TNF-alpha in response to the bacterial endotoxin lipopolysaccharide (LPS). Thus, 6-sulfo LacNAc-expressing DCs appear as a novel proinflammatory DC subset.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s1074-7613(02)00393-x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
GlcNAc6ST2/CHST4 Is Essential for the Synthesis of R-10G-Reactive Keratan Sulfate/Sulfated -Acetyllactosamine Oligosaccharides in Mouse Pleural Mesothelium.
Molecules
February 2024
Univ. Lille, CNRS, UMR 8576-UGSF-Unité de Glycobiologie Structurale et Fonctionnelle, F-59000 Lille, France.
We recently showed that 6-sulfo sialyl -acetyllactosamine (LacNAc) in -linked glycans recognized by the CL40 antibody is abundant in the pleural mesothelium under physiological conditions and that these glycans undergo complementary synthesis by GlcNAc6ST2 (encoded by ) and GlcNAc6ST3 (encoded by ) in mice. GlcNAc6ST3 is essential for the synthesis of R-10G-positive keratan sulfate (KS) in the brain. The predicted minimum epitope of the R-10G antibody is a dimeric asialo 6-sulfo LacNAc.
View Article and Find Full Text PDFClinical and immunological features in ACKR1/DARC-associated neutropenia.
Blood Adv
February 2024
Center for Hematology and Regenerative Medicine, Department of Medicine, Huddinge, Karolinska Institutet, Stockholm, Sweden.
ACKR1/DARC-associated neutropenia (NP; ADAN; Online Mendelian Inheritance in Man 611862), caused by a variation in the ACKR1/DARC gene (rs2814778), is common in persons of African or Middle Eastern descent. In a cohort of 66 genetically confirmed subjects with ADAN, we show that absolute neutrophil counts (ANCs) may occasionally be lower than previously recognized (0.1 × 109-0.
View Article and Find Full Text PDFThe slan antigen identifies the prototypical non-classical CD16-monocytes in human blood.
Front Immunol
February 2024
Department of Medicine, Section of General Pathology, University of Verona, Verona, Italy.
Introduction: Peripheral monocytes in humans are conventionally divided into classical (CL, CD14CD16), intermediate (INT, CD14CD16) and non-classical (NC, CD14CD16) cells, based on their expression levels of CD14 and CD16. A major fraction of the NC-monocytes has been shown to express the 6-sulfo LacNAc (slan) antigen, but whether these slan/NC-monocytes represent the prototypical non-classical monocytes or whether they are simply a sub-fraction with identical features as the remainder of NC monocytes is still unclear.
Methods: We analyzed transcriptome (by bulk and single cell RNA-seq), proteome, cell surface markers and production of discrete cytokines by peripheral slan/NC- and slan/NC-monocytes, in comparison to total NC-, CL- and INT- monocytes.
Blood Immune Cells as Biomarkers in Long-Term Surviving Patients with Advanced Non-Small-Cell Lung Cancer Undergoing a Combined Immune/Chemotherapy.
Cancers (Basel)
October 2023
Institute of Medical Immunology, Martin Luther University Halle-Wittenberg, 06112 Halle, Germany.
An important challenge remains in identifying the baseline characteristics of cancer patients who will mostly benefit from immune checkpoint inhibitor (ICI) therapies. Furthermore, biomarkers could help in the choice of an optimal therapy duration after a primary therapy response. In this pilot study, the time courses of four different immune cell parameters were followed in 12 patients with advanced non-small-cell lung cancer (NSCLC) undergoing ICI therapy combined with chemotherapy and surviving at least 12 months.
View Article and Find Full Text PDFslan+ Monocytes Kill Cancer Cells Coated in Therapeutic Antibody by Trogoptosis.
Cancer Immunol Res
November 2023
Section of General Pathology, Department of Medicine, University of Verona, Verona, Italy.
Monocytes positive for 6-Sulfo LacNAc (slan) are a major subset of nonclassical CD14dimCD16+ monocytes in humans. We have shown that slan+ cells infiltrate lymphomas and elicit an antibody-dependent cellular cytotoxicity (ADCC) of neoplastic B cells mediated by the anti-CD20 therapeutic rituximab. Herein, by performing blocking experiments and flow cytometry analyses, as well as confocal microscopy and live-cell imaging assays, we extended the findings to other humanized antibodies and deciphered the underlying effector mechanism(s).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!